Sofinnova Partners has announced a new collaboration with Amazon Web Services to accelerate the use of artificial intelligence across life sciences innovation. The partnership is designed to strengthen Sofinnova’s investment platform while giving its portfolio companies access to advanced cloud infrastructure, technical support, and AI capabilities. The initiative reflects the growing role of AI in how healthcare, biotechnology, medtech, digital health, and sustainability-focused companies are built and scaled.
Sofinnova Deepens Its AI Strategy
The collaboration forms part of Sofinnova.AI, the firm’s broader strategy to embed artificial intelligence across its investment and company-building activities. Through this initiative, AI is being used to support areas such as opportunity sourcing, investment evaluation, portfolio development, and market intelligence. Central to the strategy is Sofia, Sofinnova’s proprietary AI platform, which is now set to expand beyond internal use.
Sofia has so far been used by Sofinnova’s teams to analyze deal flow and generate insights across multiple life sciences sectors. With AWS, the firm plans to develop a founder-facing version of the platform that will give entrepreneurs access to practical AI-driven tools. These tools are expected to support competitive analysis, asset benchmarking, partnership mapping, and licensing intelligence.
Support for Portfolio Companies
Sofinnova-backed companies will be able to access AWS resources tailored to the needs of life sciences startups. The collaboration is intended to help companies progress more efficiently from early research through development and toward commercialization. By combining Sofinnova’s sector knowledge with AWS’s cloud and AI services, the firms aim to reduce operational barriers that often slow innovation.
Life sciences companies frequently face challenges when adopting AI, including high infrastructure costs, fragmented workflows, and the need to manage sensitive scientific and clinical data securely. AWS’s cloud capabilities are expected to provide scalable infrastructure that can support demanding research workloads. Sofinnova’s role will be to bring domain expertise, investment experience, and its Sofia platform into a more integrated support model for founders.
Industry Context
AI is increasingly shaping the way new therapies, diagnostics, devices, and healthcare solutions are discovered and developed. For emerging companies, the ability to analyze scientific data, assess competitive markets, and identify strategic opportunities quickly can be critical to success. Sofinnova’s collaboration with AWS highlights how venture capital firms are moving beyond financing to provide technology-enabled infrastructure for company creation.
Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, said AI is becoming central to how therapies are discovered, developed, and delivered to patients. He noted that Sofinnova.AI and Sofia are intended to strengthen both the firm’s investment approach and the companies it supports. He added that working with AWS reflects Sofinnova’s belief that the next generation of life sciences leaders will be built in new ways.
AWS Brings Cloud and Life Sciences Expertise
AWS brings long-standing experience working with pharmaceutical, healthcare, and life sciences organizations. Dan Sheeran, Vice President and General Manager for Healthcare and Life Sciences at AWS, said the company is proud to support future life sciences innovation through the collaboration. He highlighted AWS’s work with leading pharmaceutical companies and said the effort aims to help new therapies and solutions reach the market faster and at scale.
The collaboration also comes at a time when demand for compute power and AI-enabled research tools is increasing across the life sciences industry. As companies generate larger volumes of scientific, clinical, and market data, scalable infrastructure is becoming more important. Sofinnova sees this shift as structural, with AI expected to influence both investment decision-making and long-term value creation.
About Sofia and Sofinnova
Sofia is Sofinnova Partners’ proprietary AI platform developed to support investment analysis and company building in life sciences. The system brings together tools for scientific review, clinical assessment, market mapping, and pitch deck analysis. It is powered by more than five decades of Sofinnova’s internal data and is continuously enriched through the firm’s investment activity.
Sofinnova Partners is a European venture capital firm focused on life sciences, healthcare, and sustainability. Founded in 1972, the firm is headquartered across Paris, London, and Milan and has backed more than 500 companies globally. Today, Sofinnova manages more than €4 billion in assets and supports companies from seed stage through later-stage development.
The collaboration between Sofinnova Partners and AWS marks a significant step in applying AI more deeply to life sciences investing and entrepreneurship. By expanding Sofia into a founder-facing platform and connecting portfolio companies with AWS’s technical resources, Sofinnova aims to make AI adoption more accessible and actionable for startups. The initiative underscores a broader industry shift in which venture capital, cloud infrastructure, and AI are converging to support faster and more scalable life sciences innovation.